What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
Edoxaban demonstrated moderate benefit over warfarin in preventing stroke and systemic embolism, achieving non-inferiority in the ENGAGE AF-TIMI 48 trial. The hazard ratio for the primary efficacy endpoint was 0.79, indicating a statistically significant reduction in events compared to warfarin. However, the superiority analysis did not reach statistical significance, suggesting that while edoxaban is effective, the margin of benefit is modest.
Does the economic case hold at the expected price? — Cost effectiveness
Is there quality-of-life evidence payers weigh? — Quality of life
The HRQoL data collected via the EQ-5D questionnaire showed that only 60% of patients provided data, leading to concerns about the completeness and reliability of the results. The ERG noted difficulties in interpreting the data due to low response rates, making it challenging to draw firm conclusions about the impact of edoxaban on quality of life.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Edoxaban exhibited a significantly reduced rate of major bleeding compared to warfarin, with a hazard ratio of 0.80 for major bleeding events. However, there was a noted increase in gastrointestinal bleeding, which is a concern. Overall, the safety profile is favorable, but the presence of some serious adverse events warrants monitoring.
Was the drug compared against what payers expect? — Comparator Selection
The primary trial compared edoxaban directly with warfarin, which is the current standard of care. The inclusion of other newer anticoagulants in the network meta-analysis provides a comprehensive view of edoxaban’s position relative to its competitors, although the robustness of the network meta-analysis results was questioned.
Is the population defined the way payers need it? — Patient Population and Subgroups
The ENGAGE AF-TIMI 48 trial included a large and diverse population of over 21,000 patients with non-valvular atrial fibrillation, making the results broadly generalizable. Subgroup analyses were conducted based on risk factors and renal function, although some limitations were noted in the interpretation of these results.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Edoxaban can be integrated into existing care pathways with minimal disruption, as it is an oral anticoagulant that does not require extensive new infrastructure or training. The recommendations for its use align with current clinical practices for managing atrial fibrillation.
Are the wider system costs understood? — Resource Use and Cost Implications
While the initial cost of edoxaban is manageable, the overall resource implications raise concerns due to its cost-effectiveness profile. The economic model indicated a significant burden on the healthcare system, suggesting that while it may be affordable on a per-patient basis, the broader implications could be challenging.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The primary evidence comes from a well-conducted Phase III trial (ENGAGE AF-TIMI 48) with a large sample size and rigorous methodology. However, some concerns were raised regarding the assumptions made in the network meta-analysis, which could affect the robustness of comparative effectiveness conclusions.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
There are notable uncertainties regarding the cost-effectiveness of edoxaban compared to other newer anticoagulants, particularly due to the reliance on network meta-analysis data that may not be robust. The potential for varying outcomes based on patient characteristics adds to the uncertainty surrounding its broader impacts.
